Comparative analysis of fingolimod versus teriflunomide in relapsing-remitting multiple sclerosis

BOZ, CAVİT; TERZİ, MURAT; Ozer, Bilge; Turkoglu, Recai; KARABUDAK, RANA; EFENDİ, HÜSNÜ; Soysal, Aysun; Sevim, Serhan; Altintas, Ayse; Kurne, Asli; AKÇALI, AYLİN; Akman, Gulsen; Yuceyar, Nur; Balci, Belgin; EKMEKCİ, ÖZGÜL; Karahan, Serap; Demirkiran, Meltem; Altunrende, Burcu; TURAN, ÖMER; GozubatikCelik, Gokcen; Kale, Nilufer; Koseoglu, Mesrure; ÖZAKBAŞ, SERKAN

doi:10.1016/j.msard.2019.101376

Comparative analysis of fingolimod versus teriflunomide in relapsing-remitting multiple sclerosis

Atıf İçin Kopyala

BOZ C., TERZİ M., Ozer B., Turkoglu R., KARABUDAK R., EFENDİ H., ...Daha Fazla

MULTIPLE SCLEROSIS AND RELATED DISORDERS, cilt.36, 2019 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 36
Basım Tarihi: 2019
Doi Numarası: 10.1016/j.msard.2019.101376
Dergi Adı: MULTIPLE SCLEROSIS AND RELATED DISORDERS
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Karadeniz Teknik Üniversitesi Adresli: Evet

Özet

Background: Fingolimod and teriflunomide are commonly used in the treatment of relapsing-remitting multiple sclerosis (RRMS). These have not been compared in controlled trials, but only in observational studies, with inconclusive results. Comparison of their effect on relapse and disability in a real-world setting is therefore needed.